Chronic pain can affect a person’s life in a myriad of ways. Asal Shirazi BEM, Founder of the Autoimmune Support & Awareness Foundation (ASA Foundation), talks us through some of the conditions associated with chronic pain and the advancements in pain management.
David Nutt FMedSci, Chair Drug Science and PAREA, Prof of Neuropsychopharmacology at Imperial College London, explains why Europe needs to catch up with psychedelic research.
Researchers discover drug combination that could offer a better prognosis for children diagnosed with MYC amplified Medulloblastoma, an often deadly form of brain cancer.
Despite the rising incidence of Central Nervous System diseases worldwide, efficient treatment options for neurological disorders remain scarce. Treatment failures are principally associated with the inability of drugs to pass the highly selective Blood-Brain Barrier rather than a lack of efficacy.
Reflecting on the recent World Antimicrobial Awareness Week (WAAW 2022), it’s evident that we must continue to raise better awareness and understanding of antimicrobial resistance, which is one of the top 10 global public health threats facing humanity.
After decades of failure for Alzheimer’s researchers, Lecanemab could open the door to a new ear of drugs to treat Alzheimer’s disease – the world's most common form of dementia.
A survey looking at ayahuasca dangers finds 70% experience physical and 55% mental health adverse effects – but only 2.3% of physical adverse events require medical attention.
Dr Zisis Kozlakidis and Dr Dewi Nur Aisyah examine Hepatitis C virus elimination and weigh up if this has the potential to become a global success story.
